EUVIMEDEUVIMED entdecken
Crossref

Evaluation of EGFR Mutation Testing Concordance Between Next‐Generation Sequencing and Biocartis Idylla Console in NSCLC

Vidusha Wijesinghe iD, Mary Jones, Leonie Wheeldon iD

Cytopathology · 14.07.2026

DOI: 10.1111/cyt.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytopathology, online erschienen am 14.07.2026. Verfasst von Vidusha Wijesinghe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Royal Cornwall Hospitals NHS Trust, Truro, England. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to evaluate the concordance of in‐house epidermal growth factor receptor ( EGFR ) mutation testing using the Biocartis Idylla (Idylla) platform compared with next‐generation sequencing (NGS) for formalin‐fixed, paraffin‐embedded (FFPE) and liquid based cytology (LBC) samples. A secondary objective was to investigate the role of rapid on‐site evaluation (ROSE) in optimising sample adequacy, ensuring sufficient material is collected to facilitate comprehensive molecular testing in cases of lung adenocarcinoma.

Methods

This retrospective study used data collected on patients between November 2022 and September 2024, a total of 180 samples, in which EGFR mutations were tested for using MiSEQ Next generation sequencing (NGS) platform or the Idylla Console. The source of the data was from the Royal Cornwall Histopathology Department.

Results

Among 180 samples tested, 14 (7.78%) expressed various EGFR mutations by either NGS and/or the Idylla platform. Concordance was observed in 12 of the 14 cases (86%). However, NGS identified 2 mutations in which Idylla was unable to identify. Whilst Idylla was able to identify one EGFR Exon 21 L858R mutation in a sample in which NGS was unable to test due to insufficient material. LBC samples consistently demonstrated a higher sample quality for testing. With significantly lower CQ values on average 20.94 compared to 22.28 than that of FFPE samples ( p = 0.00151 3.s.f).

Conclusions

The Idylla Console demonstrates high concordance with NGS and effectively complements molecular diagnostics in resource and time‐constrained settings. 5.5% of cases tested using the NGS resulted in insufficient or failed testing suggesting a need for multi‐platform testing. LBC samples, particularly with the utilisation of ROSE, enhance testing quality and efficiency, offering a robust alternative to FFPE samples.

Schlagwörter

Stichwörter der Autor:innen

EGFR (epidermal growth factor receptor)formalin‐fixed paraffin embedded (FFPE)liquid based cytology (LBC)next generation sequencing (NGS)non‐small cell lung carcinoma (NSCLC)rapid onsite evaluation (ROSE)

Autor:innen und Institutionen

  • Royal Cornwall Hospitals NHS Trust, Truro, England.
  • Department of Histopathology, Royal Cornwall Hospitals NHS Trust, Truro, England.

ORCID-Profile: Vidusha Wijesinghe, Leonie Wheeldon

Zitieren

APA

Wijesinghe, V., Jones, M., & Wheeldon, L. (2026). Evaluation of EGFR Mutation Testing Concordance Between Next‐Generation Sequencing and Biocartis Idylla Console in NSCLC. Cytopathology. https://doi.org/10.1111/cyt.70109

Vancouver

Wijesinghe V, Jones M, Wheeldon L. Evaluation of EGFR Mutation Testing Concordance Between Next‐Generation Sequencing and Biocartis Idylla Console in NSCLC. Cytopathology. 2026. doi:10.1111/cyt.70109

BibTeX
@article{Wijesinghe2026,
  author = {Wijesinghe, Vidusha and Jones, Mary and Wheeldon, Leonie},
  title = {Evaluation of EGFR Mutation Testing Concordance Between Next‐Generation Sequencing and Biocartis Idylla Console in NSCLC},
  journal = {Cytopathology},
  year = {2026},
  doi = {10.1111/cyt.70109}
}
Kostenlos starten →